Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

Regulatory support - US market for innovative breast cancer diagnostic test

Reference number
Coordinator Biovica International AB
Funding from Vinnova SEK 192 708
Project duration December 2019 - June 2020
Status Completed
Venture Medtech4Health: Competence Enhancement in SME

Purpose and goal

The purpose of the project is to acquire the knowledge needed to effectively write and submit a submission to the US Food and Drug Administration (FDA) regarding an innovative in vitro diagnostics product. An approval from FDA is a prerequisite for selling and marketing a medical device in the US market.

Expected results and effects

The project has gone according to plan and given the company the necessary knowledge to be able to submit a successful sybmission to the FDA. For the company, an FDA approval is important and is a prerequisite for being able to market and sell DiviTum for clinical use in the USA.

Planned approach and implementation

The Vinnova grant has been used to secure relevant expertise necessary for the FDA submission. During the project, consultants have contributed to the company´s work to establish the FDA submission. The consultants have trained the company´s staff and have provide advice and consulting assistance in the work with regard to the technical documentation.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 20 November 2020

Reference number 2019-05566

Page statistics